Emergent to resume J&J COVID-19 vaccine production at Baltimore plant
A letter from the FDA said the agency had no objections with the plant resuming manufacturing.
Emergent Biosolutions said on Wednesday it would resume production of Johnson & Johnson's COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.
"We are proud to be resuming production of bulk COVID-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners," Chief Executive Officer Robert Kramer said.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The Wall Street Journal, which first reported the news, cited a letter from the U.S. Food and Drugs Administration (FDA) saying the agency had no objections with the plant resuming manufacturing.
U.S. authorities in April halted operations at the Baltimore plant following a discovery that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.
FDA, J&J NEAR DEAL FOR COVID-19 VACCINE PRODUCTION AT BALTIMORE PLANT
An FDA inspection had also turned up a long list of sanitary problems and bad manufacturing practices.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| EBS | EMERGENT BIOSOLUTIONS INC. | 10.12 | +0.01 | +0.10% |
| JNJ | JOHNSON & JOHNSON | 155.01 | -0.39 | -0.25% |
The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Journal said, citing a source.
CLICK HERE TO READ MORE ON FOX BUSINESS
Johnson & Johnson and the FDA did not immediately respond to Reuters requests for comment.
(Reporting by Aishwarya Nair and Maria Ponnezhath in Bengaluru; Editing by Subhranshu Sahu and Ramakrishnan M.)